December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liminatus Pharma, Inc. - Class A Common Stock (NQ:LIMN)

2.641 +0.121 (+4.80%)
Delayed Quote Updated: 9:52 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Liminatus Pharma, Inc. - Class A Common Stock

News headline image
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Transaction Expected to Close July 2, 2026 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Announces Nasdaq Delisting Notification
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Transaction Adds Clinical and Preclinical CAR-T Programs Targeting Hematologic Malignancies and Solid Tumors 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
From Liminatus Pharma, Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation 
From Liminatus Pharma Inc.
Via GlobeNewswire
News headline image
Power Metallic (TSX.V: PNPN) (OTCQB: PNPNF) Strikes Big at Lion Zone – Major Discovery Near Nisk Ignites Investor Buzz – More Stocks Inside
Via AB Newswire
Topics Economy
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.